Management of submacular haemorrhage in age-related macular degeneration with intravitreal tenecteplase

Background and aims We have previously reported that the thrombolytic tenecteplase (TNK) is able to penetrate the retina following an intravitreal injection of 50 Î¼g with no evidence of retinal toxicity. 1-3 The purpose of this report, which is the first in humans, is to assess its efficacy and saf...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of ophthalmology 2010-02, Vol.94 (2), p.260-261
Hauptverfasser:	McAllister, Ian L, Chen, Simon D, Patel, Jignesh I, Fleming, Ben L, Yu, Dao-Yi
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences drugs Fibrinolytic Agents - therapeutic use Heart attacks Humans Injections, Intraocular macula Macular degeneration Macular Degeneration - complications Medical sciences Miscellaneous Ophthalmology Retina Retinal Hemorrhage - drug therapy Retinopathies Tissue Plasminogen Activator - therapeutic use treatment surgery Visual Acuity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and aims We have previously reported that the thrombolytic tenecteplase (TNK) is able to penetrate the retina following an intravitreal injection of 50 Î¼g with no evidence of retinal toxicity. 1-3 The purpose of this report, which is the first in humans, is to assess its efficacy and safety in the management of patients with submacular haemorrhage (SMH) secondary to age-related macular degeneration.
ISSN:	0007-1161 1468-2079
DOI:	10.1136/bjo.2009.158170